Kanger gets biotechnology board's greenlight on China Covid-19 vaccine

COVID-19 | Kanger International Berhad announced that the National Institutes of Biotechnology Malaysia (NIBM) has issued a letter stating it has no objections for the company to communicate with Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.

This followed Kanger’s announcement on Sept 29 that the group, which is chaired by former deputy minister Nur Jazlan Mohamed, entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd.

The deal is for the distribution of Covid-19 vaccines and medical equipment in Malaysia developed by China National Pharmaceutical Group Corporation (Sinopharm)...